Error message

Deprecated function: implode() [function.implode]: Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /var/www/medbac.dk/public_html/includes/common.inc).

Abundant human anti-Galα3Gal antibodies display broad pathogen reactivity.

TitleAbundant human anti-Galα3Gal antibodies display broad pathogen reactivity.
Publication TypeJournal Article
Year of Publication2020
AuthorsJensen, JMagnus Ber, Petersen, MSteen, Ellerman-Eriksen, S, Møller, BKuno, Jensenius, JChristian, Sørensen, UBSkov, Thiel, S
JournalSci Rep
Volume10
Issue1
Pagination4611
Date Published2020 03 12
ISSN2045-2322
KeywordsAntibodies, Disaccharides, Enzyme-Linked Immunosorbent Assay, Escherichia coli, Escherichia coli Infections, Host-Pathogen Interactions, Humans, Immunoglobulin G, Sepsis
Abstract

Antibodies of the IgG class to terminal Galα3Gal (IgG anti-αGal) is abundant in human plasma and are reported to bind most sepsis-causing Gram-negative bacteria. However, these seminal findings, made more than two decades ago, have not been reexamined. Our aim was to assess IgG anti-αGal´s pathogen reactivity. We affinity purified IgG anti-αGal from a therapeutic grade normal human IgG pool applying two rounds of positive selection with Galα3Gal-coupled beads and included removal of column matrix reactive antibodies. The purified antibodies were rigorously characterized in terms of specificity and purity in various solid-phase immunoassays. We used flow cytometry to study reactivity against 100 consecutive clinical isolates diagnosed as cause of sepsis in humans. We found that the purified IgG anti-αGal displays high specificity for Galα3Gal. Also, IgG anti-αGal at 5 mg/L bound 56 out of 100 pathogens with predilection for Gram-positive bacteria binding 39 out of 52 strains. We confirm that although IgG anti-αGal comprise a small fraction of the human antibody pool (~0.1%), these antibodies targets an impressively large part of pathogens causing invasive disease.

DOI10.1038/s41598-020-61632-9
Alternate JournalSci Rep
PubMed ID32165720
PubMed Central IDPMC7067764